Seeking patients with renal cell carcinoma for interviews

Dear Cancer Patient:We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who arecurrently taking orconsidering taking a chemotherapy agent.These interviews are scheduled forMonday, September 29 and the morning ofTuesday, September 30  in our offices at:Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview will last 60 minutes and the cash honorarium is $150This is not sales. All information will be completely confidential. Please call me at312-604-4000 extension 215 between the hours of 9 AM and 4:00 Monday throughFriday to schedule a time or obtain more information.Thank you for your consideration of this important study. David Carr09/11/2008
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

CONCLUSION: Pancreas is not a common location for metastases; however, colon, stomach, kidney and lung seem to be the most common primary tumors with metastases to the pancreas. Our report is the first study about pancreatic metastatic tumors from Iran. PMID: 30821161 [PubMed - in process]
Source: Archives of Iranian Medicine - Category: Middle East Health Authors: Tags: Arch Iran Med Source Type: research
Publication date: Available online 14 November 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Maria V. Chatziathanasiadou, Evgenios K. Stylos, Efstathia Giannopoulou, Maria-Helen Spyridaki, Evangellos Briasoulis, Haralabos P. Kalofonos, Tim Crook, Nelofer Syed, Gregory B. Sivolapenko, Andreas G. TzakosAbstractSunitinib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor and is currently being investigated against other forms of malignant tumors. Recently a great interest has been emerged for the appli...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
This article also provides an overview of: (1) general information on PDGFR kinase inhibitors; (2) pharmacokinetic parameters of PDGFR kinase inhibitors; (3) metabolic enzymes and transporters of PDGFR kinase inhibitors; (4) main drug interactions of PDGFR kinase inhibitors; (5) adverse events of PDGFR kinase inhibitors; and (6) genetic polymorphism on pharmacokinetics and pharmacodynamics of PDGFR kinase inhibitors. PMID: 29956623 [PubMed - as supplied by publisher]
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research
AimsKIT overexpression is frequently observed in adenoid cystic carcinomas (AdCCs), chromophobe renal cell carcinomas (ChRCCs), and gastrointestinal stromal tumours (GISTs). Persistent KIT activation has been reported to be mediated by protein kinase C (PKC)‐δ in a subset of colon cancers with wild‐type KIT overexpression, and by PKC‐θ in GISTs with mutant KIT overexpression. To elucidate the clinical implications of PKC‐δ and PKC‐θ expression in KIT‐expressing tumours, we investigated the expression of KIT, PKC‐δ and PKC‐θ in AdCCs and ChRCCs in comparison with GISTs. Me...
Source: Histopathology - Category: Pathology Authors: Tags: Original Article Source Type: research
Abstract AimsKIT overexpression is frequently observed in adenoid cystic carcinomas (AdCCs), chromophobe renal cell carcinomas (ChRCCs), and gastrointestinal stromal tumor (GISTs). Persistent KIT activation has been reported to be mediated by protein kinase C (PKC)‐δ in a subset of colon cancers with wild‐type KIT overexpression and by PKC‐θ in GISTs with mutant KIT overexpression. To elucidate the clinical implications of PKC‐δ and PKC‐θ expression in KIT‐expressing tumors, we investigated the expression of KIT, PKC‐δ, and PKC‐θ in AdCCs and ChRCCs in comparison to GISTs...
Source: Histopathology - Category: Pathology Authors: Tags: Original Article Source Type: research
We present the key trials and data for sunitinib that established it as a reference standard of care for first-line advanced RCC therapy and, along with other targeted agents, significantly altered the treatment landscape in RCC. Moreover, we discuss the research with sunitinib that has sought to refine its role via patient selection and prognostic markers, improve dosing and adverse event management, and identify predictive efficacy biomarkers, plus the extent to which this research has contributed to the overall understanding and management of RCC. We also explore the key learnings regarding study design and data interpr...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Review, Genitourinary Cancer Source Type: research
Authors: Ahmed AA, Abedalthagafi M Abstract Although histomorphology has made significant advances into the understanding of cancer etiology, classification and pathogenesis, it is sometimes complicated by morphologic ambiguities, and other shortcomings that necessitate the development of ancillary tests to complement its diagnostic value. A new approach to cancer patient management consists of targeting specific molecules or gene mutations in the cancer genome by inhibitory therapy. Molecular diagnostic tests and genomic profiling methods are increasingly being developed to identify tumor targeted molecular profil...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 13 August 2016 Source:Chemico-Biological Interactions Author(s): Yi Yang, Peili Bu Tyrosine kinase inhibitors (TKIs) are multi-targeted anti-cancer agents effective in the treatment of renal cell carcinoma (RCC), imatinib-resistant gastrointestinal stromal tumor (GIST) and pancreatic cancer (PC). Targeting and inhibiting a wide range of oncogenically relevant receptor tyrosine kinases (RTKs), TKIs have been the golden standard treatment of several types of cancer. The cardiotoxicity of TKIs, however, has also emerged alongside their anti-cancer potencies and has attracted research attent...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Abstract Tyrosine kinase inhibitors (TKIs) are multi-targeted anti-cancer agents effective in the treatment of renal cell carcinoma (RCC), imatinib-resistant gastrointestinal stromal tumor (GIST) and pancreatic cancer (PC). Targeting and inhibiting a wide range of oncogenically relevant receptor tyrosine kinases (RTKs), TKIs have been the golden standard treatment of several types of cancer. The cardiotoxicity of TKIs, however, has also emerged alongside their anti-cancer potencies and has attracted research attention. Over the past few years significant progress has been made in developing a deeper understanding ...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
In this study, CD171 expression was immunohistochemically analyzed in 5155 epithelial, mesenchymal, melanocytic, and lymphohematopoietic tumors to assess its utility in diagnostic pathology and to pinpoint potential targets for CD171-targeting therapy. A newly developed anti-CD171 rabbit monoclonal antibody, clone 014, was selected from the panel of commercially available CD171 antibodies. Immunohistochemistry was performed using Leica Bond Max automation and multitumor blocks containing up to 60 tumor samples. CD171 was constitutively and strongly expressed in neuroectodermal tumors such as schwannoma, neuroblastoma, and ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology